Evidence map›Paper›PMID 39531096›Full record

SynthesisInternational journal of clinical oncology2025

Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.

Kazuhisa Nakashima, Saki Harashima, Rena Kaneko, Ryuhei Tanaka, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K Imamura and 18 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Kazuhisa NakashimaDepartment of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-Cho, Izumo, Shimane, 693-8501, Japan.
Saki HarashimaDepartment of Psychosomatic Medicine, Faculty of Medicine, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Rena KanekoDepartment of Gastroenterology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-Cho, Kanagawa, 211-8510, Japan.
Ryuhei TanakaDepartment of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350‑1298, Japan.
Masakazu AbeDepartment of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1‑20‑1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431‑3192, Japan.
Makoto WadaDepartment of Psycho-Oncology, Osaka International Cancer Institute, 3-1‑69, Chuo-Ku, Osaka, 541‑8567, Japan.
Keiko IinoSchool of Nursing, National College of Nursing, Japan, 1-2‑1, Umezono, Kiyose, Tokyo, 204‑8575, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive‑Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho‑Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501‑1194, Japan.
Chiyo K ImamuraAdvanced Cancer Translational Research Institute, Showa University, 1‑5‑8 Hatanodai, Shinagawa‑Ku, Tokyo, 142‑8555, Japan.
Ayako OkuyamaGraduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104‑0044, Japan.
Keiko OzawaDivision of Survivorship Institute for Cancer Control, National Cancer Center, 5‑1‑1 Tsukiji, Chuo-Ku, Tokyo, 104‑0045, Japan.
Yong-Il KimDivision of Medical Oncology, Yodogawa Christian Hospital, 1‑7‑50 Kunijima, Higasiyodogawa-Ku, Osaka, Osaka, 533‑0024, Japan.
Eriko SatomiDepartment of Palliative Medicine, National Cancer Center Hospital, 5‑1‑1 Tsukiji Chuo-ku, Tokyo, 104‑0045, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634‑8521, Japan.
Takako Eguchi NakajimaDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Shogoin, Sakyo-Ku, Kyoto, 606‑8507, Japan.
Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1‑69, Osaka, 541‑8567, Japan.
Mayumi NodaNon-Profit Organization Sasaeau-Kai "Alpha", 518-7 Kawado-Cho, Chuo-Ku, Chiba, 260‑0802, Japan.
Kazumi HayashiDepartment of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3‑25‑8 Nishi‑Shinnbashi Minatoku, Tokyo, 105‑8461, Japan.
Takahiro HigashiDepartment of Public Health and Health Policy, The University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑0033, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4‑6‑1 Shiroganedai, Minato-Ku, Tokyo, 108‑8639, Japan.
Koji MatsumotoDivision of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-Cho, Akashi, Hyogo, 673‑0021, Japan.
Yoko MatsumotoNon-Profit Organization Ehime Cancer Support Orange-No-Kai, 3‑8‑24 Furukawaminami, Matsuyama, Ehime, 790‑0943, Japan.
Kenji OkitaDepartment of Surgery, Otaru Ekisaikai Hospital, 1-4‑1, Inaho, Otaru, Hokkaido, 047‑0032, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641‑8509, Japan.
Kenjiro AogiDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama, Ehime, 791‑0280, Japan.
Hidenori SasakiDivision of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45‑1, Nanakuma, Jonan‑Ku, Fukuoka, 814‑0180, Japan. hsasaki@fukuoka-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA standardized multi-day antiemetic regimen for multi-day chemotherapy remains elusive. This systematic review evaluated the efficacy and safety of multi-day antiemetic regimens in patients undergoing multi-day intravenous chemotherapy.

methodsWe conducted a comprehensive search of PubMed, Cochrane Library, and Ichushi-Web databases for relevant studies published from January 1990 to December 2020. We included studies comparing multi-day and single-day antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.

resultsNo studies directly comparing multi-day versus single-day antiemetic regimens were found. Despite expanding control group criteria beyond "single-day antiemetic therapy" limited high-quality studies and variations in cancer types, chemotherapy regimens, and antiemetic treatments precluded meta-analysis. Among the included studies, some randomized controlled trials (RCTs) focused on complete response and vomiting rates. Two studies comparing two- and three-drug combinations reported higher complete response and no-vomiting rates with the three-drug regimen. Limited RCTs explored "nausea control" and "cost," and assessing "adverse events" proved challenging due to inconsistent reporting.

conclusionThe research on multi-day antiemetic therapy is limited, necessitating further investigation. Nonetheless, our findings suggest that three-drug combination therapy, including aprepitant, may offer superior antiemetic efficacy compared to two-drug regimens. Multi-day antiemetic therapy is strongly recommended during multi-day intravenous administration of cytotoxic anticancer drugs.

Indexed as

AntiemeticsNauseaNeoplasmsVomitingAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleHumansJapanMedical OncologyPractice Guidelines as TopicAntiemeticsAntineoplastic AgentsChemotherapy-induced nausea and vomitingMeta-analysisMulti-day chemotherapySystematic review

Identifiers

PMID39531096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.